2021 Global Inflammatory Bowel Disease Treatment Market Report: Strong Product Lines, Emergence of Biosimilars, Regulatory Agency Participation in Funding and Designation-Forecast to 2028 – QNT Press Release


Dublin, November 8, 2021 (Global News Agency) – “Inflammatory bowel disease treatment market size, sharing and trend analysis report, forecast by type (Crohn’s disease, ulcerative colitis), by drug category, by route of administration, by distribution channel, by region and segment, 2021 -2028” Report has been added to ResearchAndMarkets.com supply.

By 2028, the global inflammatory bowel disease treatment market is expected to reach US$27.8 billion, and it is expected to grow at a compound annual growth rate of 4.8% from 2021 to 2028.

Increasing awareness of the disease, the increase in the elderly population and the favorable measures taken by the regulatory agencies are expected to drive market growth during the forecast period. For example, in January 2020, the US FDA allowed ABIVAX to conduct ABX464 Phase 2B clinical trials in patients with moderate to severe ulcerative colitis in the United States.

It is expected that increasing adoption of new product development and expansion strategies will drive market growth. For example, Takeda Pharmaceuticals was approved by the US FDA in June 2020 to produce Entyvio (Vedolizumab) at its US manufacturing facility. The approval is expected to support the growing demand for the drug in the United States and neighboring countries. In addition, Takeda Pharmaceuticals is investing heavily in the development of the Chinese market.

The initiatives taken by organizations to respond to the challenges of… development have increased.

The full story on Benzinga.com



Source link

Recommended For You

About the Author: News Center